Luminex Corporation Reports First Quarter 2019 Financial Results
AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter 2019. Financial and operating highlights for the quarter include:
-- First quarter consolidated revenue of $82.4 million compared to the
first quarter 2018 revenue of $82.7 million.
-- In the first quarter, flow cytometry contributed revenue of
approximately $11.4 million, offsetting the revenue loss of LabCorp
Women's Health.
-- Royalty revenue of $14.2 million grew 16% over the first quarter 2018.
This reflects $149 million of royalty-bearing end user sales on Luminex
technology, an increase of approximately 10% over the comparable period
in 2018.
-- Sample-to-Answer revenue grew 16% over the 1(st) quarter of 2018 and we
placed approximately 50 sample-to-answer molecular systems under
contract during the first quarter of 2019. Active sample-to-answer
customers approximated 625 in the quarter.
-- Gross margins of 56% in the first quarter, directly affected by the
departure of LabCorp revenue coupled with the Flow Cytometry acquisition
and integration.
-- First quarter GAAP net income was approximately $3.0 million, or $0.07
per diluted share, primarily driven by a discrete tax benefit of $6.6
million in the current quarter related to a tax benefit emanating from
the Company's Canadian subsidiary. On a non-GAAP basis, the Company had
a net loss of $3.0 million, or losses of $0.07 per diluted share (see
Non-GAAP reconciliation).
"I am pleased with our first quarter results and the continued progress we are making across the company," said Nachum "Homi" Shamir, President & CEO. "I am very excited about our future. We have two more quarters to go until we emerge as a much more diversified company with increasing momentum that is past the loss of LabCorp," continued Shamir. "During this time, we will continue to build a strong foundation through both our sample to answer portfolio and life sciences businesses. By the end of this year, we believe Luminex will be growing at a double digit rate, have improved gross margins, and will return to consistent profitability and cash flow."
REVENUE SUMMARY
(in thousands, except percentages)
Three Months Ended
March 31, Variance
---
2019 2018
($) (%)
---
(unaudited)
System
sales $15,671 $7,931 $7,740 98%
Consumable
sales 10,724 11,872 (1,148) -10%
Royalty
revenue 14,170 12,239 1,931 16%
Assay
revenue 34,813 45,841 (11,028) -24%
Service
revenue 5,394 2,878 2,516 87%
Other
revenue 1,636 1,901 (265) -14%
$82,408 $82,662 $(254) 0%
===
FINANCIAL OUTLOOK AND GUIDANCE
The Company intends to provide annual revenue guidance, to be updated, as appropriate, at each quarterly reporting period. Luminex anticipates its second quarter 2019 revenue to be between $80 million and $83 million and reaffirms its full year 2019 revenue guidance of between $337 million and $343 million.
CONFERENCE CALL
Management will host a conference call at 3:30 p.m. CDT / 4:30 p.m. EDT, Monday, May 6, 2019 to discuss the operating highlights and financial results for the first quarter 2019. The conference call will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the 'replay' link.
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at www.luminexcorp.com.
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding expected revenue and cost savings and projected 2019 performance, including revenue guidance. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, concentration of Luminex's revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex's technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of internal resource planning challenges; market demand and acceptance of Luminex's products and technology, including ARIES(®), MultiCode(®), xMAP(®), VERIGENE(®), Guava(®), Muse(®), Amnis(®) and NxTAG(®) products; Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels; Luminex's ability to obtain and enforce intellectual property protections on Luminex's products and technologies; the impact on Luminex's growth and future results of operations with respect to the loss of the LabCorp women's health business; Luminex's ability to successfully launch new products in a timely manner; dependence on strategic partners for development, commercialization and distribution of products; risks and uncertainties associated with implementing Luminex's acquisition strategy, Luminex's challenge to identify acquisition targets, including Luminex's ability to obtain financing on acceptable terms; Luminex's ability to integrate acquired companies or selected assets, including the Flow-Cytometry assets recently acquired from Millipore Sigma, into Luminex's consolidated business operations, and the ability to fully realize the benefits of Luminex's acquisitions; the timing of and process for regulatory approvals; competition and competitive technologies utilized by Luminex's competitors; fluctuations in quarterly results due to a lengthy and unpredictable sales cycle; fluctuations in bulk purchases of consumables; fluctuations in product mix, and the seasonal nature of some of Luminex's assay products; Luminex's ability to comply with applicable laws, regulations, policies and procedures; the impact of the ongoing uncertainty in global finance markets and changes in governmental and governmental agency funding, including effects on the capital spending policies of Luminex's partners and end users and their ability to finance purchases of Luminex's products; changes in principal members of Luminex's management staff; potential shortages, or increases in costs, of components or other disruptions to Luminex's manufacturing operations; Luminex's increasing dependency on information technology to improve the effectiveness of Luminex's operations and to monitor financial accuracy and efficiency; the implementation, including any modification, of Luminex's strategic operating plans; the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex; risks relating to Luminex's foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; Luminex's ability to monitor and comply with foreign and international laws and treaties; and Luminex's ability to comply with changes in international taxation policies; budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges; reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements, including the financial guidance and 2019 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Contacts:
Harriss T. Currie
David Carey
Sr. Vice President, Finance and Chief Financial Officer
Investor Relations, Lazar Partners
512-219-8020
212-867-1768
hcurrie@luminexcorp.com
dcarey@lazarpartners.com
LUMINEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
March 31,
December 31,
2019 2018
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $61,689 $76,441
Accounts receivable, net 62,652 53,396
Inventories, net 64,027 63,250
Prepaids and other 8,917 9,657
Total current assets 197,285 202,744
Property and equipment, net 65,630 66,288
Intangible assets, net 98,891 105,148
Deferred income taxes 28,334 21,470
Goodwill 118,293 118,127
Right of use assets 23,824 -
Other 11,244 11,398
Total assets $543,501 $525,175
===
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $18,138 $14,504
Accrued liabilities 22,728 26,772
Deferred revenue -current
portion 8,521 10,099
Total current liabilities 49,387 51,375
Deferred revenue 3,038 1,079
Lease liabilities 20,792 -
Other 1,827 5,065
Total liabilities 75,044 57,519
Stockholders' equity:
Common stock 44 44
Additional paid-in capital 366,049 365,349
Accumulated other
comprehensive loss (1,260) (1,127)
Retained earnings 103,624 103,390
Total stockholders' equity 468,457 467,656
Total liabilities and
stockholders' equity $543,501 $525,175
===
LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three Months Ended
March 31,
2019 2018
---
(unaudited)
Revenue $82,408 $82,662
Cost of revenue 36,601 29,074
Gross profit 45,807 53,588
Operating expenses:
Research and
development 15,048 10,326
Selling, general and
administrative 31,491 25,830
Amortization of
acquired intangible
assets 2,852 2,166
Total operating
expenses 49,391 38,322
---
Income (loss) from
operations (3,584) 15,266
Other income, net 60 449
Income (loss) before
income taxes (3,524) 15,715
Income tax benefit
(expense) 6,484 (2,318)
---
Net income $2,960 $13,397
Net income attributable to common stock
holders
Basic $2,904 $13,192
Diluted $2,904 $13,192
Net income per share attributable to common stock
holders
Basic $0.07 $0.30
Diluted $0.07 $0.30
Weighted-average shares used in computing net income
per share
Basic 43,949 43,462
Diluted 44,546 43,633
Dividends declared
per share $0.06 $0.06
LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Three Months Ended
March 31,
2019 2018
---
(unaudited)
Cash flows from operating activities:
Net income $2,960 $13,397
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 6,889 5,893
Stock-based compensation 2,449 1,261
Deferred income tax (benefit) expense (8,087) 1,453
Loss on sale or disposal of assets 94
Other (242) 31
Changes in operating assets and liabilities:
Accounts receivable, net (7,342) 5,556
Inventories, net (486) (2,735)
Other assets 2,272 (203)
Accounts payable 4,117 320
Accrued liabilities (10,400) (11,439)
Deferred revenue 680 422
---
Net cash provided by operating activities (7,096) 13,956
---
Cash flows from investing activities:
Purchase of property and equipment (3,823) (4,068)
Issuance of note receivable (500)
Acquired technology rights (4,000)
Net cash used in investing activities (3,823) (8,568)
---
Cash flows from financing activities:
Proceeds from issuance of common stock 802 1,126
Shares surrendered for tax withholding (2,072) (2,003)
Dividends paid (2,696) (2,624)
Net cash used in financing activities (3,966) (3,501)
---
Effect of foreign currency exchange rate on cash 133 (344)
Change in cash and cash equivalents (14,752) 1,543
Cash and cash equivalents, beginning of period 76,441 127,112
---
Cash and cash equivalents, end of period $61,689 $128,655
===
LUMINEX CORPORATION
NON-GAAP RECONCILIATION
(in thousands)
Three Months Ended
March 31,
2019 2018
---
(unaudited)
Reported Net Income $2,960 $13,397
Severance & costs
associated with legal
proceedings 148 20
Income tax effect of above
adjusting items (17) (3)
Income tax effect from
discrete tax items (6,087) (2,532)
Adjusted Net Income (loss) $(2,996) $10,882
===
Adjusted net income (loss)
per share, basic $(0.07) $0.25
Shares used in computing
adjusted net income per
share, basic 43,949 43,462
Adjusted net income (loss)
per share, diluted $(0.07) $0.25
Shares used in computing
adjusted net income per
share, diluted 44,546 43,633
The Company makes reference in this release to "non-GAAP net loss" which excludes costs associated with legal proceedings, severance costs, and discrete tax impacts; some of which are unpredictable and can vary significantly from period to period; and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. In addition, the Company's management uses such non-GAAP measures internally to evaluate and assess its core operations and to make ongoing operating decisions. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.
View original content to download multimedia:http://www.prnewswire.com/news-releases/luminex-corporation-reports-first-quarter-2019-financial-results-300844487.html
SOURCE Luminex Corporation
